Published: 2016-12-18

Oxidative stress versus inflammation, a better predictor of cardiovascular disease risk in polycystic ovary syndrome

Shimi M. Sundharan, Kavita A. Dipnaik, Pramod W. Ingale, Sudarshan N. Shelke, Pooja S. K. Rai


Background: Polycystic ovary syndrome (PCOS) is also known as hyperandrogenic anovulation (HA) or Stein-Leventhal syndrome. PCOS has a diverse range of causes that are not entirely understood, but there is evidence that it is largely a genetic disease. Aim of the study was to evaluate better predictor of cardiovascular disease risk in women with polycystic ovary syndrome.

Methods: 50 diagnosed patients of PCOS and 50 age matched healthy females were included in this study. Cases were diagnosed based on new Rotterdam criteria formulated by the American Society for Reproductive Medicine (ASRM). Fasting Blood samples were collected. Serum High sensitivity-C reactive protein (hs-CRP) and Malondialdehyde (MDA) were estimated.

Results: Results were analyzed using unpaired t-test and p-value was calculated. Statistically non-significant increased levels of serum hs-CRP in PCOS cases as compared with controls were observed. MDA was found to be significantly increased in cases as compared to controls. ROC curve analysis shows MDA as a more specific predictor of cardiovascular disease risk in PCOS compared to hs-CRP.

Conclusions: Increase in the serum MDA level indicates increased formation of reactive oxygen species and lipid peroxidation which leads to increased oxidative stress and this may increase cardiovascular disease risk in PCOS. hs-CRP a marker of chronic inflammation was not significantly increased in PCOS.



Full Text:



González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kB triggers inflammation and insulin resistance in polycystic ovary syndrome. Journal of Clin Endocrinol Metab. 2006;91:1508-12.

Piotrowski PC, Rzepczynska IJ, Kwintkiewicz J, Duleba AJ. Oxidative stress induces expression of CYP11A, CYP17, STAR and 3bHSD in rat theca-interstitial cells. J Soc Gynecol Invest. 2005;12(2):319A.

Desai V. Oxidative Stress in Non-Obese Women with Polycystic Ovarian Syndrome. J Clin Diagn Res. 2014;8(7):CC01-3.

Hadi HAR, Carr CS, Suwaidi JA. Endothelial Dysfunction: Cardiovascular Risk Factors, Therapy, and Outcome Vasc Health Risk Manag. 2005;1(3):183-98.

Vrbíková J, Cífková R, Jirkovská A, Lánská V, Platilová H, Zamrazil V, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome Human Reproduction. 2003;18(5):980-4.

Franks S. Are women with polycystic ovary syndrome at increased risk of cardiovascular disease? Too early to be sure, but not too early to act! The American Journal of Medicine. 2002;111(8):665-6.

Ridker PM, Wilson PW, Grundy SM. Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk? American heart association. 2004;109:2818-25.

Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative Stress and Antioxidant Defense World Allergy Organ J. 2012;5(1):9-19.

Tietz N.W. Clinical Guide to Laboratory Tests, 4th Edition, Alan H. Wu, Saunders Elsevier. 2006.

Mahfouz MD, Hariprasad Ch, Shaffi Sadasivudu B. Serum malonaldehyde levels in myocardial infarction and chronic renal failure. IRCS Med Sci. 1986;14:1110-11.

Möhlig M. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol. 2004;150(4):525-32.

Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453-5.

Sheehan MT. Polycystic Ovarian Syndrome: Diagnosis and Management Clin Med Res. 2004;2(1):13-27.

Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20:3333-40.

Blair SA, Kyaw-Tun, Young IS, Phelan NA, Gibney J, McEneny J. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J Reprod Med. 2013;58:107-14.

Kusçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in nonobese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009;88:612-7.

Fenkci V, Fenkci S, Yilmaz M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80:123-7.

Liu J, Zhang D. The role of oxidative stress in the pathogenesis of polycystic ovary syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012;43:187-90.

González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336-40.

González F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab. 2012;97:2836-43.

Sabuncu T, Vurul H, Harma M. Oxidative stress in polycystic ovarian syndrome and its contribution to the risk of cardiovascular diseases. J Clin Biochem. 2001;34:407-13.

Fenkci V, Fenkci S, Mehmet Y, Serteser M. Decreased total anti-oxidant status and increased oxidative stress in women with polycystic ovarian syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80:123-7.